# Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

> **NCT00782301** · PHASE4 · WITHDRAWN · sponsor: **ViiV Healthcare**

## Conditions studied

- Hepatitis B
- Human Immunodeficiency Virus
- Hepatitis C, Chronic

## Interventions

- **DRUG:** maraviroc
- **DRUG:** etravirine

## Key facts

- **NCT ID:** NCT00782301
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-03
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782301, "Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00782301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*